Reuters logo
BRIEF-Ablynx reports 9-month revenue of 16.7 mln euros
November 14, 2013 / 6:16 AM / in 4 years

BRIEF-Ablynx reports 9-month revenue of 16.7 mln euros

BRUSSELS, Nov 14 (Reuters) - Ablynx NV : * Says 9 months revenues of 16.7 mln euros * Signed exclusive global license agreement with abbvie, potentially worth $840 mln * Deal for development, commercialisation of the anti-il-6r nanobody, alx-0061, in RA and SLE * Net loss for 9-month period was 18.9 mln euros vs 22.3 mln euros last year * Says positive net cash inflow of 0.2 mln euros * Says 9-month operating expenses decreased to 36.2 mln euros vs 45.4 mln last year due to lower research and development costs * Says upfront payments as part of collaborations with Abbvie and Merck Serono were booked in fourth quarter * Started additional anti-rsv nanobody phase i studies; goal to initiate first-in-infant trial in H2 2014 * Last quarter of year has already started strongly with signing of license agreement with Eddingpharm in Greater China

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below